5-Amino-1MQ + NAD+ Oral (50 mg + 50 mg capsule)
A combination of 5-Amino-1MQ, an inhibitor of the enzyme NNMT, with NAD+. 5-Amino-1MQ has been studied preclinically. For the combination and for oral NAD+ there is no published schedule and no human study.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-10-31
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
In preclinical models, NNMT inhibition increased NAD+ inside cells (Neelakantan 2018). There are no data on whether the NAD+ in the capsule adds anything to this mechanism.
Quick Start
- Schedule for the combination: none in any source.
- 5-Amino-1MQ alone: the sources mention 50–150 mg a day by mouth, with no human study.
- Oral NAD+: no schedule. A research source states that it is largely broken down in the intestine.
What is published on the oral dose
Route: By mouth (per os), with no data for the combination | Frequency: No published schedule
peptidedosingprotocols.com and peptidedosage.org mention 50–150 mg a day for 5-Amino-1MQ only, and the former states that no human study has defined an oral dose (accessed 31/10/2026). We do not calculate a dose for the combination, because NAD+, which has no schedule, would rise along with it.
Related compounds
Protocol Overview
- 5-Amino-1MQ inhibits NNMT, an enzyme that consumes nicotinamide, a precursor of NAD+ (Neelakantan 2018).
- In rats, the oral bioavailability of 5-Amino-1MQ was measured at 38.4% (Awosemo 2021). It has not been measured in humans.
- NR and NMN studies do not concern oral NAD+ and are not used here as evidence.
Dosing Protocol
- There is no published schedule for the combination.
- Whether the two substances interact when taken together has not been studied.
Storage Instructions
- No published stability data were found for this combination in capsule form.
Important Notes
- There is no human study of the combination or of oral 5-Amino-1MQ.
- The substances have not been approved by the FDA or the EMA for this use.
Potential Benefits & Side Effects
Potential Benefits:
- In mice, subcutaneously: metabolic findings in a model of diet-induced metabolic disorder (Neelakantan 2018)
Potential Side Effects:
- The safety profile of the combination in humans is unknown.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Hepatotoxicity (preclinical)
As an NNMT inhibitor, 5-amino-1MQ has shown hepatotoxicity at high doses in rodents. No human safety studies exist.
📄 Biochem Pharmacol 2020Metabolism enhancement — potential tumor protection
NAD+ elevation may theoretically benefit cancer cells by enhancing their energy metabolism (Warburg effect). Some studies show that NAMPT inhibition (NAD synthesis enzyme) suppresses oncogenesis.
📄 Cancer Cell 2018; Nat Rev Cancer 2020Flushing & GI discomfort with IV administration
IV NAD+ commonly causes chest tightness, flushing, nausea, cramps. Subcutaneous administration reduces these but with local pain.
📄 GeroScience 2023References
- Neelakantan H et al. Biochem Pharmacol 2018 — NNMT inhibitor in mice, subcutaneous administration for 11 days.
View Source - Neelakantan H et al. Biochem Pharmacol 2019 — NNMT inhibitor and muscle stem cells in aged mice.
View Source - Awosemo O et al. J Pharm Biomed Anal 2021 — Pharmacokinetics in rats, oral bioavailability 38.4%.
View Source - peptidedosingprotocols.com: 5-Amino-1MQ — Research source for 5-Amino-1MQ alone. Accessed 31/10/2026.
View Source - peptidedosage.org: 5-Amino-1MQ — Second research source for 5-Amino-1MQ alone. Accessed 31/10/2026.
View Source - peptidedosage.org: NAD+ — Source on the breakdown of oral NAD+ in the intestine. Accessed 31/10/2026.
View Source
External Sources & Regulatory Status
Regulatory Approvals
Dietary supplement (GRAS)
Dietary supplement (GRAS)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →